A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study

A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study

Abstract Background The peak of the global COVID-19 pandemic has not yet been reached, and many countries face the prospect of a second wave of infections before effective vaccinations will be available. After an initial phase of viral replication, some patients develop a second illness phase in whi...

Full description

Bibliographic Details
Main Authors: T. Vanassche, M. M. Engelen, Q. Van Thillo, J. Wauters, J. Gunst, C. Wouters, C. Vandenbriele, S. Rex, L. Liesenborghs, A. Wilmer, P. Meersseman, G. Van den Berghe, D. Dauwe, G. Verbeke, M. Thomeer, T. Fivez, D. Mesotten, D. Ruttens, L. Heytens, I. Dapper, S. Tuyls, B. De Tavernier, P. Verhamme, DAWn consortium members
Format: Article
Language:English
Published: BMC 2020-12-01
Series:Trials
Subjects:
COVID-19
SARS-CoV-2
Low molecular weight heparins
Aprotinin
Anakinra
Thromboinflammatory response
Online Access:https://doi.org/10.1186/s13063-020-04878-y

Internet

https://doi.org/10.1186/s13063-020-04878-y

Similar Items